Negative opinion for Raxone (idebenone) in Duchenne muscular dystrophy expected.
Santhera Pharmaceuticals announced that on 23 January 2018 it had an oral explanation at the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in relation to the re-examination of its Marketing Authorization Application (MAA) for Raxone (idebenone) in Duchenne muscular dystrophy (DMD). The company now anticipates that the CHMP will maintain its original position to issue a negative opinion on Santhera's MAA filed as Type II variation of its existing marketing authorization for Leber's hereditary optic neuropathy (LHON). Santhera will provide further update on Friday, 26 January 2018 as originally announced..
Related news and insights
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the Phase IIIb COSMOS clinical trial showing that treatment with Tremfya (guselkumab) provided sustainable improvements in all minimal disease activity (MDA)a domains through week 48 in adults living with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR)
Pfizer Inc. announced the first detailed results from the Phase II PHAROS study, which is evaluating the efficacy and safety of Braftovi (encorafenib) given in combination with Mektovi(binimetinib) to patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
Legend Biotech Corp announced that results from the Phase III CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel (ciltacabtagene autoleucel) reduced the risk of disease progression or death by 74 percent compared to standard of care regimens in adult patients with multiple myeloma who have received one to three prior lines of therapy and are refractory to lenalidomide (Hazard ratio [HR]=0.26 (95% CI, 0.18–0.38); P-value [P] <0.0001)